A lung abscess is a localized area of suppuration and necrosis within the pulmonary parenchyma, forming a thick-walled cavity containing purulent material. It most commonly results from aspiration of oropharyngeal anaerobic bacteria, particularly in patients with impaired consciousness, poor dentition, or alcoholism. [1-3] Over 80% resolve with prolonged antibiotic therapy alone. [3]
1. History
- Onset and tempo: Subacute presentation over days to weeks is typical; acute onset is less common
- Cough: Present in ~79% — initially dry, progressing to productive with foul-smelling, purulent sputum (pathognomonic for anaerobic infection) [2]
- Fever: Reported in 50–57% of cases; may be low-grade and intermittent [2][4]
- Constitutional symptoms: Malaise (61%), fatigue, weight loss (62% in ICU cohorts), night sweats [2][4]
- Hemoptysis: Reported in ~22% of ICU patients [4]
- Pleuritic chest pain: Suggests peripheral abscess or empyema extension [5]
- Key questions: Aspiration risk (recent LOC, seizure, intoxication, sedation, dysphagia), dental history, recent pneumonia, IV drug use, travel history (TB-endemic areas), immunosuppression
2. Alarm Features
- Massive hemoptysis — may require bronchial artery embolization (12% of ICU cases) [4]
- Sepsis/septic shock — tachycardia, hypotension, altered mental status
- Respiratory failure — progressive dyspnea, hypoxia
- Abscess rupture into pleural space → empyema, bronchopleural fistula [3]
- Failure to improve after 7–10 days of appropriate antibiotics — consider obstruction (malignancy), resistant organisms, or need for drainage [3][6]
- Abscess >5 cm — independent risk factor for empyema (OR 9.0) [5]
3. Medications
- First-line empiric therapy (community-acquired):
- Ampicillin–sulbactam 3 g IV q6h, OR
- Clindamycin 600 mg IV q8h (historically preferred for anaerobic coverage; superior to penicillin in comparative trials), OR
- Ertapenem 1 g IV daily, OR
- Moxifloxacin 400 mg IV/PO daily [1][7]
- Hospital-acquired / MDR risk: Piperacillin–tazobactam, meropenem, or cefepime ± vancomycin/linezolid if MRSA suspected [1]
- Add clindamycin to another agent when risk of predominantly anaerobic infection is high (severe periodontal disease, putrid sputum) [1]
- Avoid metronidazole monotherapy — failed in 5/11 cases of lung abscess and was inferior to clindamycin in a randomized trial [1]
- Duration: Prolonged — median 38 days (IQR 30–51) in a large cohort; typically continued until radiographic resolution or a small stable residual cavity [1-2]
- Transition to oral: Step down to oral antibiotics (e.g., amoxicillin-clavulanate 875/125 mg PO BID, or clindamycin 300–450 mg PO QID) once clinically improving, afebrile, and tolerating PO
4. Diet
- Aspiration precautions if dysphagia or impaired consciousness is present — NPO or modified diet per swallow evaluation
- Adequate nutrition is critical given the catabolic state; hypoalbuminemia (<25 g/L) is a risk factor for empyema [5]
- Hydration to support mucociliary clearance and thin secretions
- Alcohol cessation counseling — alcohol abuse present in ~20–22% of cases [2][4]
5. Review of Systems
- Pulmonary: Cough, sputum character (putrid?), hemoptysis, dyspnea, pleuritic pain
- Constitutional: Fever, chills, night sweats, weight loss, fatigue
- GI: Dysphagia, GERD, vomiting (aspiration risk)
- Neuro: Seizures, altered consciousness, stroke history (aspiration risk)
- Dental: Tooth pain, recent dental procedures, gum disease
- Musculoskeletal/skin: Joint swelling, skin abscesses (hematogenous source — endocarditis, IVDU)
6. Collateral History and Family History
- Witnesses to aspiration events — LOC, seizure, intoxication
- Caregiver input on functional status, swallowing difficulty, sedative use (29.3% of patients used sedatives) [2]
- Social history: Alcohol use, IV drug use, homelessness, incarceration (TB risk)
- Family history is generally less relevant, though immunodeficiency syndromes should be considered in younger patients with recurrent abscesses
- Dental care access — poor dental status found in 42% of patients where documented [2]
7. Risk Factors
- Aspiration-prone states: Alcoholism, seizure disorder, sedative use, dysphagia, stroke, dementia, general anesthesia, NG tube [2-3]
- Poor dental hygiene / periodontal disease — major source of anaerobic inoculum [2][8]
- COPD (35% of patients) and structural lung disease [2]
- Immunocompromise (41% in ICU cohorts) — HIV, chemotherapy, transplant, chronic steroids [4]
- Bronchial obstruction — endobronchial tumor, foreign body [3]
- Diabetes mellitus (30% in one cohort) — independent risk factor for empyema [5][9]
- Cancer history (20.5%) [4]
- IV drug use — associated with S. aureus hematogenous abscesses [10]
- E-cigarette use — emerging concern as a potential risk factor [8]
8. Differential Diagnosis
- Cavitating lung cancer — the most dangerous mimic; must be excluded in all patients >45 years, smokers, or those not responding to antibiotics. Abscess walls tend to be thicker and more irregular in malignancy [11-12]
- Tuberculosis — indistinguishable from acute lung abscess in up to 21% of cases in endemic areas; upper lobe predilection [7]
- Necrotizing pneumonia — multiple thin-walled cavities vs. single thick-walled abscess [13]
- Empyema — CT differentiates: empyema shows the "split pleura sign," lenticular shape, and compresses adjacent lung; abscess is round and destroys lung parenchyma [14-15]
- Septic pulmonary emboli — multiple peripheral cavitating nodules; consider endocarditis, Lemierre syndrome, IVDU [13]
- Fungal infection (aspergillosis, mucormycosis, coccidioidomycosis) — especially in immunocompromised; fungal infection is an independent predictor of ICU mortality (OR 9.12) [4]
- Granulomatosis with polyangiitis (GPA) — cavitating nodules with renal involvement [11]
- Congenital pulmonary airway malformation — in younger patients [13]
9. Past Medical History
- Prior aspiration events or pneumonia
- History of lung abscess (recurrence suggests obstruction or immunodeficiency)
- Seizure disorder, stroke, neuromuscular disease
- COPD, bronchiectasis, prior thoracic surgery
- Malignancy — especially lung, head/neck
- Immunosuppressive conditions or medications
- Dental history and last dental evaluation
10. Physical Exam
- Vital signs: Fever (may be absent in elderly/immunocompromised), tachycardia, tachypnea, hypoxia
- Oral exam: Periodontal disease, dental caries, gingivitis — critical and often overlooked
- Pulmonary: Decreased breath sounds, dullness to percussion, bronchial breath sounds, amphoric breathing over large cavities, crackles
- Signs of aspiration risk: Depressed gag reflex, pooling of secretions
- Clubbing: May develop with chronic abscess
- Cachexia/wasting: Suggests prolonged illness
- Skin: Track marks (IVDU), stigmata of liver disease (alcoholism)
- Cardiac: Murmur (endocarditis as source of septic emboli)
11. Lab Studies
- CBC: Leukocytosis with left shift; anemia of chronic disease in subacute cases
- CRP / ESR: Elevated; useful for monitoring treatment response
- Procalcitonin: May help differentiate bacterial from non-bacterial etiology
- BMP: Assess renal function (antibiotic dosing); renal replacement therapy is an independent mortality predictor (OR 3.56) [4]
- Albumin: Hypoalbuminemia (<25 g/L) is a risk factor for empyema [5]
- LFTs: Baseline for prolonged antibiotic therapy
- Blood cultures: Obtain before antibiotics (positive in a minority but guides therapy)
- Sputum culture (aerobic + anaerobic): Low yield for anaerobes due to contamination; putrid sputum is essentially diagnostic of anaerobic infection
- AFB smear and culture: Rule out TB, especially in endemic areas or atypical presentations [7]
- HIV testing: If risk factors present or immunocompromise suspected
- Fungal markers (β-D-glucan, galactomannan): If immunocompromised [4]
12. Imaging
- Chest X-ray (first-line): Thick-walled cavity with an air-fluid level is the classic finding; may show surrounding consolidation. Sensitivity is limited — can miss early abscess and may not distinguish from empyema [13][16]
- CT chest with IV contrast (gold standard): [14-15]
- Round, thick-walled cavity within lung parenchyma
- Enhancing wall with internal air-fluid level
- Surrounding consolidation
- Differentiates abscess from empyema (abscess: round, destroys parenchyma, forms acute angles with chest wall; empyema: lenticular, split pleura sign, compresses lung)
- CT correctly diagnosed 100% of cases in one comparative study [15]
- Detects complications: empyema, bronchopleural fistula, endobronchial obstruction
- Lung ultrasound: Useful at bedside for pleural effusion assessment; limited for parenchymal abscess
- Follow-up imaging: Repeat CT to assess response; radiographic resolution lags behind clinical improvement by weeks to months
13. Special Tests
- Bronchoscopy: Indicated when obstruction (tumor, foreign body) is suspected, atypical presentation, or failure to respond to antibiotics. Protected specimen brush or BAL for culture [7]
- CT-guided percutaneous aspiration: For culture when sputum is non-diagnostic and organisms are needed to guide therapy [7][17]
- Metagenomic next-generation sequencing (mNGS): Emerging tool with superior detection of anaerobes (e.g., Parvimonas micra, Peptostreptococcus) compared to conventional culture [9][12]
- CURB-65 or PSI: May be applied for initial severity assessment of the underlying pneumonia
14. ECG
- Routine ECG if septic, hemodynamically unstable, or elderly
- Assess for sinus tachycardia (sepsis, dehydration)
- Rule out right heart strain (new right axis deviation, S1Q3T3) if concern for septic pulmonary emboli
- Evaluate for endocarditis-related findings if hematogenous source suspected (IVDU)
15. Assessment
- Primary vs. secondary abscess: Primary results from aspiration in patients with risk factors (alcoholism, poor dentition, impaired consciousness). Secondary results from bronchial obstruction (tumor), hematogenous spread (endocarditis, IVDU), or extension from extrapulmonary infection (liver abscess → lung) [3][10]
- Microbiology: Community-acquired — anaerobes predominate (44% pure anaerobic, 22% mixed), followed by aerobic streptococci (27%) and S. aureus (17%). Hospital-acquired/ICU — Enterobacteriaceae (31%), S. aureus (22%), P. aeruginosa (19%), polymicrobial (36%) [4][7][10]
- Severity stratification: Abscess >5 cm, transpulmonary fissure extension, diabetes, and pleuritic symptoms are independent risk factors for empyema. Fungal infection is the strongest predictor of ICU mortality (OR 9.12) [4-5]
- Mortality: 1-month mortality ~2.7%, 12-month mortality ~15.8%; ICU mortality 21.5% [2][4]
16. Treatment Plan
Initial stabilization
- ABCs, supplemental O2, IV access, fluid resuscitation if septic
- Position patient with abscess side dependent if massive hemoptysis (protect unaffected lung)
Antibiotic therapy
- Start empiric IV antibiotics immediately after cultures obtained
- Community-acquired: Ampicillin–sulbactam 3 g IV q6h or clindamycin 600 mg IV q8h ± a fluoroquinolone [1]
- Hospital-acquired/MDR risk: Piperacillin–tazobactam 4.5 g IV q6h or meropenem 1 g IV q8h ± vancomycin [1]
- Step down to oral therapy when improving: amoxicillin-clavulanate or clindamycin
- Total duration: typically 4–6 weeks minimum (median 38 days), guided by clinical and radiographic response [2]
Drainage / intervention (for refractory cases)
- >80% resolve with antibiotics alone [3]
- Percutaneous catheter drainage (PCD): For peripheral abscesses failing medical therapy; 83% complete resolution rate; complications include bleeding, empyema, bronchopleural fistula (16% complication rate) [3][6]
- Endoscopic catheter drainage (ECD): For central abscesses or patients with coagulopathy; lower complication rate than PCD with similar success [6]
- Surgical resection (lobectomy/segmentectomy): Reserved for massive hemoptysis, suspected malignancy, bronchopleural fistula, or failure of all other measures (~13% of ICU cases) [4]
- Bronchial artery embolization: For significant hemoptysis (12% of ICU cases) [4]
Adjunctive measures
- Postural drainage with abscess side dependent
- Dental evaluation and treatment of periodontal disease
- Swallow evaluation if aspiration risk
- Nutritional support
17. Disposition
Admission criteria
- Nearly all patients with newly diagnosed lung abscess require inpatient admission for IV antibiotics (median hospitalization 14 days, IQR 7–21) [2]
- Sepsis, respiratory failure, hemoptysis, inability to tolerate PO
- Need for drainage procedure or surgical consultation
Observation / step-down
Discharge criteria
- Afebrile, clinically improving, tolerating oral antibiotics
- Reliable outpatient follow-up arranged
- No ongoing hemoptysis or respiratory compromise
Specialist consultation triggers
- Pulmonology: Bronchoscopy for suspected obstruction, atypical presentation, or non-response
- Interventional radiology: CT-guided percutaneous drainage
- Thoracic surgery: Massive hemoptysis, bronchopleural fistula, suspected malignancy, failed drainage
- Infectious disease: Complex microbiology, immunocompromised host, MDR organisms
- Dentistry: Periodontal disease management
18. Follow Up / Return Precautions
- Follow-up timing: Clinical reassessment within 1–2 weeks of discharge; repeat imaging at 4–6 weeks and again at completion of antibiotics [18]
- Antibiotic monitoring: CBC, CRP, renal/hepatic function periodically during prolonged therapy; monitor for C. difficile colitis [1]
- Radiographic resolution lags behind clinical improvement — cavities may persist for weeks to months; complete resolution confirmed in ~91% with follow-up imaging [18]
- Bronchoscopy should be considered if abscess does not resolve to exclude underlying malignancy, especially in patients >45 years, smokers, or those with atypical location (non-dependent segments) [7]
- Return precautions: Worsening fever, increasing sputum production, hemoptysis, chest pain, shortness of breath, inability to tolerate oral medications
- Long-term: Address modifiable risk factors — alcohol cessation, dental care, aspiration precautions, smoking cessation. 12-month all-cause mortality is notably high at ~16%, underscoring the importance of close follow-up [2]
References
1. Aspiration Pneumonia. — Mandell LA, Niederman MS. The New England Journal of Medicine. 2019.
2. Lung Abscess: Clinical Characteristics of 222 Danish Patients Diagnosed From 2016 to 2021. — Vaarst JK, Sperling S, Dahl VN, et al. Respiratory Medicine. 2023.
3. ACR Appropriateness Criteria® Radiologic Management of Infected Fluid Collections. — Weiss CR, Bailey CR, Hohenwalter EJ, et al. Journal of the American College of Radiology : JACR. 2020.
4. Epidemiology and Clinical Patterns of Lung Abscesses in ICU: A French Multicenter Retrospective Study. — Montméat V, Bonny V, Urbina T, et al. Chest. 2023.
5. Logistic Regression Analysis of Clinical and Computed Tomography Features of Pulmonary Abscesses and Risk Factors for Pulmonary Abscess-Related Empyema. — Cai XD, Yang Y, Li J, et al. Clinics. 2019.
6. Lung Abscess: The Non-Conservative Management: A Narrative Review. — Hadid W, Stella GM, Maskey AP, Bechara RI, Islam S. Journal of Thoracic Disease. 2024.
7. The Etiology and Antimicrobial Susceptibility Patterns of Microorganisms in Acute Community-Acquired Lung Abscess. — Hammond JM, Potgieter PD, Hanslo D, Scott H, Roditi D. Chest. 1995.
8. Lung Abscess: An Update on the Current Knowledge and Call for Future Investigations. — Sperling S, Dahl VN, Fløe A. Current Opinion in Pulmonary Medicine. 2024.
9. Heterogeneity in Clinical Patterns of Adult Lung Abscess Patients: An 8-Year Retrospective Study in a Tertiary Hospital. — Zhang R, Yu J, Shang X, et al. BMC Pulmonary Medicine. 2025.
10. Aetiology of Adult Community-Acquired Lung Abscess in Hong Kong. — Yu WC, Ho MY, Yu EL, et al. Respirology. 2025.
11. Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach. — Gafoor K, Patel S, Girvin F, et al. Chest. 2018.
12. Rapidly Progressive Pulmonary Abscess Initially Misdiagnosed as Lung Cancer: The Role of Peptostreptococcus Stomatis and Parvimonas Micra. — Hu H, Li K, Jin Z, Wang K, Liu B. Frontiers in Cellular and Infection Microbiology. 2025.
13. Complicated Pneumonia in Children. — de Benedictis FM, Kerem E, Chang AB, et al. Lancet. 2020.
14. ACR Appropriateness Criteria® Acute Respiratory Illness in Immunocompetent Patients: 2024 Update. — Batra K, Walker CM, Little BP, et al. Journal of the American College of Radiology : JACR. 2025.
15. Differentiating Lung Abscess and Empyema: Radiography and Computed Tomography. — Stark DD, Federle MP, Goodman PC, Podrasky AE, Webb WR. AJR. American Journal of Roentgenology. 1983.
16. Community-Acquired Pneumonia in Adults. — Bai AD, Loeb M. NEJM Evidence. 2025.
17. Thoracic Trauma WSES-AAST Guidelines. — Coccolini F, Cremonini C, Moore EE, et al. World Journal of Emergency Surgery : WJES. 2025.
18. Clinical Presentation and Management Outcomes of Pediatric Lung Abscess: A Retrospective Cohort Study. — Alshadfan L, Abualhaj S, Kilani M, et al. PloS One. 2025.